RANI (Rani Therapeutics Holdings) Interest Expense : $-4.68 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Rani Therapeutics Holdings's interest expense for the three months ended in Mar. 2025 was $ -0.94 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $-4.68 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Rani Therapeutics Holdings's Operating Income for the three months ended in Mar. 2025 was $ -12.01 Mil. Rani Therapeutics Holdings's Interest Expense for the three months ended in Mar. 2025 was $ -0.94 Mil. Rani Therapeutics Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rani Therapeutics Holdings Interest Expense Historical Data

The historical data trend for Rani Therapeutics Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings Interest Expense Chart

Rani Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.12

-0.47

-1.07

-5.09

-5.03

Rani Therapeutics Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-1.29	-1.28	-1.34	-1.12	-0.94

Rani Therapeutics Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.68 Mil.

Rani Therapeutics Holdings (NAS:RANI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rani Therapeutics Holdings's Interest Expense for the three months ended in Mar. 2025 was $-0.94 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-12.01 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was $9.34 Mil.

Rani Therapeutics Holdings's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Rani Therapeutics Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Rani Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2051 Ringwood Avenue, San Jose, CA, USA, 95131

Website

https://www.ranitherapeutics.com

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Executives

Kate Mckinley	officer: CHIEF BUSINESS OFFICER	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Talat Imran	director, officer: CEO	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Cone Investments Limited Partnership	10 percent owner	AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Quiroga Cortes Isidoro Alfonso	10 percent owner	9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Svai S Sanford	officer: CFO	C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen	officer: General Counsel	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim	officer: Chief Scientific Officer	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership	10 percent owner	LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran	director
Andrew Farquharson	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono	director
Lisa Ann Rometty	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131